Fidaxomicin inhibits toxin production in Clostridium difficile | Zendy

Farah Babakhani | Zendy; Laurent Bouillaut | Zendy; P.S. Sears | Zendy; Christopher E. Sims | Zendy; Andrés Santiago Aristizábal Gómez | Zendy; Abraham L. Sonenshein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fidaxomicin inhibits toxin production in Clostridium difficile

Author(s) -

Farah Babakhani,

Laurent Bouillaut,

P.S. Sears,

Christopher E. Sims,

Andrés Santiago Aristizábal Gómez,

Abraham L. Sonenshein

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks450

Subject(s) - fidaxomicin , clostridium difficile , clostridium difficile toxin a , microbiology and biotechnology , vancomycin , toxin , clostridium difficile toxin b , metronidazole , biology , antibiotics , bacteria , staphylococcus aureus , genetics

Fidaxomicin, which was recently approved for the treatment of Clostridium difficile-associated diarrhoea, demonstrates narrow-spectrum bactericidal activity via inhibition of RNA polymerase. In this study we evaluated its inhibitory activity versus C. difficile toxin gene expression and toxin production by quantifying toxin mRNA and protein.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research